Arrowhead Research Corporation (ARWR) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproductio...
Arrowhead Research Corporation's revenue increased 23258.2% year over year, from $3.6M to $829.4M.
Net income increased 99.7% over the same period, from $-599.5M to $-1.6M.
Total debt decreased by 45.3% to $214.9M.
The debt-to-equity ratio stands at 0.46, indicating a moderate leverage profile.
Operating cash flow grew 138.8% to $179.6M.
Arrowhead Research Corporation maintains a negative net profit margin of -0.2%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $0 | $-170.8M | N/A | $-176.1M | $-115.4M | $883.8M | $448.1M | $330.5M |
| Q4 FY2024 | $0 | $-170.5M | N/A | $-162.2M | $-137.2M | $1.14B | $393.2M | $185.4M |
| Q1 FY2025 | $2.5M | $-173.1M | N/A | $-161.4M | $-146.3M | $1.01B | $407.8M | $52.6M |
| Q2 FY2025 | $542.7M+21608.4% | $370.4M | N/A | $381.2M | $460.1M | $1.57B | $208.9M | $683.3M |
| Q3 FY2025 | $27.8M-94.9% | $-175.2M | N/A | $-165.6M | $-154.7M | $1.38B | $200.3M | $522.3M |
| Q4 FY2025 | $256.5M+823.7% | $-23.8M | N/A | $44.1M | $20.5M | $1.39B | $214.9M | $466.1M |
| Q1 FY2026 | $264.0M+2.9% | $30.8M | N/A | $40.8M | $13.5M | $1.60B | $163.1M | $568.4M |
| Q2 FY2026 | $73.7M-72.1% | $-132.7M | N/A | $-141.3M | $84.4M | $2.27B | $159.6M | $614.0M |
Balance Sheet Summary (Latest Period)
Arrowhead Research Corporation (ARWR) Financial Statements & Revenue History
Arrowhead Research Corporation (ARWR) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $68.09 with a market capitalization of $10. This page provides 42 historical financial statements for Arrowhead Research Corporation, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Arrowhead Research Corporation reported revenue of $829 million, representing 23258.2% year-over-year growth. The net profit margin of -0.2% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.46 shows conservative leverage.
ARWR Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Arrowhead Research Corporation's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ARWR is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ARWR's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Arrowhead Research Corporation converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ARWR's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ARWR Financial Data
Investors use Arrowhead Research Corporation's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ARWR's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ARWR's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ARWR's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Arrowhead Research Corporation's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ARWR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.